Premium
Therapeutic potential of the anti‐angiogenesis drug TNP‐470
Author(s) -
Gervaz,
Fontolliet
Publication year - 1998
Publication title -
international journal of experimental pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.671
H-Index - 72
eISSN - 1365-2613
pISSN - 0959-9673
DOI - 10.1046/j.1365-2613.1998.00087.x
Subject(s) - angiogenesis , drug , clinical trial , medicine , cancer research , drug development , key (lock) , pharmacology , oncology , biology , ecology
Neovessel formation is a pre‐requisite for tumour growth and dissemination. Inhibition of angiogenesis is a promising approach for the treatment of neoplasms. In recent years, antiangiogenic drugs, such as TNP‐470, have entered clinical trials. In this paper, we review the key experimental and clinical data on the role of TNP‐470 in anti‐tumour treatment.